ReviewChinese medical journal2019
Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.
Review in Chinese medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- When cellulitis isn't cellulitis: A case of rapidly progressive cutaneous hemorrhagic bullae and purpura with mucosal involvement.JAAD case reports · 2026Article
- Coexisting Hepatic and Renal Dysfunction During Pulmonary Tuberculosis Treatment: A Case Report.Clinical case reports · 2026Article
- Hydralazine-induced antineutrophil cytoplasmic antibody vasculitis with significant dermatologic manifestations.JAAD case reports · 2026Article
- Prevalence and types of anti-neutrophil cytoplasmic antibodies in patients with nephrotic syndrome treated with levamisole.Pediatric nephrology (Berlin, Germany) · 2026Article
- Hemoptysis as the initial presentation of ANCA-associated vasculitis in a patient with ulcerative colitis: a case report and literature review.Clinical rheumatology · 2026Review
- Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report.Current drug safety · 2026Review
- From Thyroid Therapy to Systemic Crisis: PTU-Induced c-ANCA Vasculitis Accompanied by Cold-Agglutinin Disease and Organ Failure.European journal of case reports in internal medicine · 2026Article
- Drug-Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches-A Narrative Review.Health science reports · 2025Article
- Hydralazine-Induced ANCA Vasculitis Presenting With Pericarditis: A Novel Case and Literature Review.Case reports in cardiology · 2025Article
- Propylthiouracil-induced vasculitis with alveolar hemorrhage after 31 years of treatment: a case report.Clinical diabetes and endocrinology · 2024Article
- Renal-Limited Presentation of Hydralazine-Induced Anti-neutrophil Cytoplasmic Antibody Vasculitis: A Case Report.Cureus · 2024Article
- Pathogenesis of Pulmonary Manifestations in ANCA-Associated Vasculitis and Goodpasture Syndrome.International journal of molecular sciences · 2024Review
- Article
- ANCA-associated vasculitis presenting with isolated neurological manifestations in a patient with cocaine abuse: a case report and literature review.Clinical rheumatology · 2024Review
- Acute interstitial nephritis caused by ANCA-associated vasculitis: a case based review.Clinical rheumatology · 2024Review
- Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2024Article
- Antineutrophil Cytoplasmic Antibody Vasculitis after Coronary Artery Bypass Grafting.Case reports in surgery · 2024Article
- The potential immunomodulatory effect of levamisole in humans and farm animals.Journal of advanced veterinary and animal research · 2023Review
- Hepatic steatosis index at diagnosis has the potential for forecasting end-stage kidney disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Journal of rheumatic diseases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn recent years, an increasing number of drugs have been proved to be associated with the induction of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This article reviews the latest research progress on drug-induced AAV. DATA SOURCES: We conducted a comprehensive and detailed search of the PubMed database. The search terms mainly included drug-induced, ANCA, and vasculitis. STUDY SELECTION: We summarized the original articles and reviews on drug-induced AAV in recent years. The extracted information included the definition, epidemiology, associated drugs, pathogenesis, clinical features, diagnosis, treatment, and prognosis of drug-induced AAV. We also focused on the differences between drug-induced AAV and primary vasculitis.
resultsThe offending drugs leading to drug-induced AAV are almost from pharmacologic categories and we need to be vigilant when using these drugs. The pathogenesis of drug-induced AAV might be multifactorial. The formation of neutrophil extracellular traps is an important mechanism for the development of drug-induced AAV. The clinical features of drug-induced AAV are similar to those of primary AAV. Understanding the difference between drug-induced AAV and primary AAV is helpful to identify drug-induced AAV. Stopping the offending drug at once after diagnosis may be sufficient for those patients with mild symptoms. Immunosuppressive therapy should only be used in patients with vital organs involvement.
conclusionsPatients with drug-induced AAV usually have a good prognosis if they stop using the offending drug immediately. Recent advances in research on AAV are expected to help us better understand the pathogenesis of drug-induced AAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.